
  
    
      
        Introduction_NNP
        The_DT immunotherapy_NN of_IN cancer_NN holds_VBZ promise_NN in_IN harnessing_VBG the_DT host_NN immune_JJ response_NN to_TO
        specifically_RB target_VB tumor_NN cells_NNS without_IN harming_VBG normal_JJ tissues_NNS ._. Strategies_NNS involve_VBP adoptive_JJ
        cellular_JJ therapy_NN or_CC active_JJ immune_JJ induction_NN (_( commonly_RB referred_VBD to_TO as_IN “ cancer_NN vaccination_NN” )_) ._.
        Cancer_NN vaccines_NNS may_MD consist_VB of_IN whole_JJ tumor_NN cells_NNS or_CC tumor_NN lysates_NNS ,_, but_CC identification_NN of_IN
        tumor-associated_JJ antigens_NNS (_( TAAs_NNP )_) over_IN the_DT past_JJ decade_NN has_VBZ made_VBN possible_JJ the_DT use_NN of_IN specific_JJ
        proteins_NNS or_CC peptides_NNS as_IN cancer_NN vaccines_NNS ._. The_DT anti-tumor_JJ potential_NN of_IN TAA-specific_NNP CD_NNP 8_CD +_NN T_NN
        cells_NNS has_VBZ been_VBN illustrated_VBN by_IN the_DT demonstrated_VBN capacity_NN of_IN adoptive_JJ T_NN cell_NN therapy_NN to_TO
        reduce_VB tumor_NN size_NN [_NN 1_CD ]_NN ._. While_IN endogenous_JJ anti-tumor_JJ CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS may_MD already_RB exist_VB
        in_IN some_DT cancer_NN patients_NNS [_NN 2_CD ]_NN ,_, vaccination_NN with_IN TAA-derived_NNP peptides_NNS ,_, and_CC in_IN particular_JJ
        heteroclitic_JJ peptide_NN analogs_NNS ,_, increases_VBZ the_DT frequency_NN of_IN TAA-specific_NNP T_NN cell_NN responses_NNS to_TO
        detectable_JJ levels_NNS in_IN many_JJ patients_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. Heteroclitic_NNP peptide_NN analogs_NNS are_VBP
        created_VBN by_IN substitutions_NNS at_IN anchor_NN residues_NNS resulting_VBG in_IN increased_VBN association_NN of_IN peptide_NN
        with_IN the_DT major_JJ histocompatibility_NN complex_JJ (_( MHC_NNP )_) [_NN 10_CD ]_NN ._. Consequently_RB ,_, heteroclitic_JJ peptide_NN
        analogs_NNS are_VBP predicted_VBN to_TO be_VB more_RBR immunogenic_JJ than_IN their_PRP$ native_JJ counterparts_NNS because_IN of_IN more_RBR
        stable_JJ binding_VBG at_IN the_DT surface_NN of_IN antigen-presenting_JJ cells_NNS (_( APCs_NNP )_) ._. Indeed_RB ,_, T_NN cells_NNS capable_JJ
        of_IN tumor_NN lysis_NNS have_VBP been_VBN isolated_VBN from_IN patients_NNS vaccinated_JJ with_IN heteroclitic_JJ peptide_NN
        [_NN 8_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ]_NN ._. However_RB ,_, the_DT presence_NN of_IN TAA-specific_NNP T_NN cells_NNS elicited_JJ by_IN vaccination_NN often_RB
        does_VBZ not_RB correlate_VBP with_IN clinical_JJ responses_NNS [_NN 3_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ]_NN ._.
        Various_JJ reasons_NNS for_IN the_DT paradoxical_JJ coexistence_NN of_IN cancer_NN cells_NNS and_CC TAA-specific_NNP T_NN cells_NNS
        within_IN patients_NNS have_VBP been_VBN proposed_VBN [_NN 18_CD ,_, 19_CD ]_NN ._. One_CD possibility_NN is_VBZ that_IN elicited_JJ TAA-specific_NNP T_NN
        cells_NNS are_VBP not_RB optimally_RB functional_JJ in_IN vivo_NN [_NN 2_CD ,_, 18_CD ]_NN ._. Another_DT possibility_NN is_VBZ that_IN T_NN cells_NNS
        inefficient_JJ in_IN tumor_NN recognition_NN or_CC lysis_NNS are_VBP induced_VBN by_IN vaccination_NN [_NN 20_CD ]_NN ._. It_PRP is_VBZ becoming_VBG
        recognized_VBN that_IN antigen-specific_JJ T_NN cells_NNS may_MD have_VB substantially_RB different_JJ requirements_NNS for_IN
        cognate_NN peptide_NN (_( the_DT peptide_NN that_WDT is_VBZ recognizable_JJ to_TO a_DT specific_JJ T_NN cell_NN clone_NN )_) for_IN efficient_JJ
        target_NN lysis_NNS [_NN 20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ]_NN ._. “ Recognition_NN efficiency_NN” (_( RE_NNP )_) (_( also_RB known_VBN as_IN “ functional_JJ
        avidity_NN” )_) is_VBZ a_DT measure_NN of_IN the_DT sensitivity_NN of_IN a_DT T_NN cell_NN to_TO different_JJ peptide_NN concentrations_NNS
        for_IN stimulation_NN [_NN 24_CD ,_, 25_CD ,_, 26_CD ]_NN ._. We_PRP hypothesized_VBN that_IN high_JJ antigen_NN densities_NNS on_IN APCs_NNP resulting_VBG
        from_IN vaccination_NN with_IN heteroclitic_JJ peptide_NN may_MD paradoxically_RB drive_VB T_NN cells_NNS of_IN predominantly_RB
        low_JJ RE_NNP ,_, which_WDT are_VBP not_RB efficiently_RB activated_VBN by_IN the_DT endogenous_JJ expression_NN levels_NNS of_IN native_JJ
        peptides_NNS on_IN tumor_NN cells_NNS ._. Consequently_RB ,_, such_JJ T_NN cells_NNS would_MD be_VB ineffective_JJ in_IN tumor_NN cell_NN
        destruction_NN ._. Support_NN for_IN this_DT notion_NN is_VBZ emerging_VBG :_: T_NN cells_NNS with_IN low_JJ RE_NNP are_VBP predominantly_RB
        expanded_VBN in_IN vitro_NN with_IN high_JJ peptide_NN concentration_NN [_NN 22_CD ]_NN ._. Moreover_RB ,_, in_IN vitro_NN stimulation_NN of_IN T_NN
        cells_NNS from_IN healthy_JJ donors_NNS with_IN heteroclitic_JJ peptides_NNS results_NNS in_IN expansion_NN of_IN cells_NNS with_IN a_DT
        wide_JJ range_NN of_IN RE_NNP [_NN 23_CD ]_NN ._. A_DT similar_JJ phenomenon_NN may_MD occur_VB in_IN vivo_NN ,_, leading_VBG to_TO TAA-specific_NNP T_NN
        cells_NNS of_IN low_JJ RE_NNP depending_VBG on_IN the_DT nature_NN of_IN antigen_NN stimulation_NN [_NN 20_CD ]_NN ._.
        While_IN isolated_VBN T_NN cell_NN clones_NNS with_IN low_JJ RE_NNP have_VBP indeed_RB been_VBN generated_VBN from_IN melanoma_NN
        patients_NNS following_VBG heteroclitic_JJ peptide_NN vaccination_NN ,_, the_DT proportion_NN of_IN vaccine-elicited_JJ T_NN
        cell_NN responses_NNS these_DT cells_NNS represent_VBP in_IN vivo_NN is_VBZ not_RB clear_JJ ._. If_IN predominantly_RB high-_NN RE_NNP ,_,
        tumor-cytolytic_JJ T_NN cells_NNS are_VBP generated_VBN ,_, then_RB a_DT small_JJ fraction_NN of_IN low-_JJ RE_NNP T_NN cells_NNS generated_VBN
        would_MD be_VB of_IN little_JJ consequence_NN ._. However_RB ,_, if_IN predominantly_RB low-_JJ RE_NNP T_NN cells_NNS are_VBP generated_VBN ,_,
        then_RB this_DT low_JJ proportion_NN of_IN high-_NN RE_NNP T_NN cells_NNS may_MD be_VB an_DT important_JJ factor_NN in_IN the_DT observed_VBN lack_NN
        of_IN clinical_JJ effectiveness_NN of_IN current_JJ cancer_NN vaccination_NN strategies_NNS ._. To_TO address_VB this_DT
        important_JJ issue_NN ,_, we_PRP undertook_VBD a_DT systematic_JJ examination_NN of_IN the_DT complexity_NN of_IN T_NN cell_NN
        responses_NNS induced_VBN by_IN heteroclitic_JJ peptide_NN vaccination_NN ,_, and_CC compared_VBD these_DT responses_NNS to_TO
        endogenous_JJ anti-tumor_JJ T_NN cell_NN responses_NNS which_WDT develop_VBP in_IN some_DT patients_NNS ._. Typically_RB ,_, responses_NNS
        to_TO vaccination_NN are_VBP examined_VBN following_VBG in_IN vitro_NN expansion_NN from_IN patient_NN samples_NNS ,_, which_WDT may_MD
        alter_VB the_DT composition_NN of_IN cells_NNS and_CC consequently_RB not_RB reveal_VB the_DT proportion_NN of_IN cells_NNS in_IN vivo_NN
        having_VBG sufficiently_RB high_JJ RE_NNP to_TO lyse_NN tumor_NN targets_NNS ._. Although_IN staining_VBG with_IN peptide–_NN MHC_NNP
        tetramers_NNS provides_VBZ a_DT direct_JJ estimate_NN for_IN the_DT number_NN of_IN TAA-specific_NNP T_NN cells_NNS present_JJ in_IN
        vivo_NN ,_, and_CC intensity_NN of_IN tetramer_NN staining_VBG has_VBZ been_VBN employed_VBN as_IN a_DT parameter_NN for_IN isolation_NN of_IN
        high-_NN RE_NNP ,_, tumor-lytic_JJ T_NN cells_NNS [_NN 27_CD ]_NN ,_, staining_VBG intensity_NN does_VBZ not_RB correlate_VBP well_RB with_IN RE_NNP or_CC
        tumor-lytic_JJ potential_JJ [_NN 28_CD ,_, 29_CD ]_NN ,_, and_CC cannot_NN be_VB considered_VBN a_DT reliable_JJ indicator_NN for_IN the_DT
        functional_JJ status_NN of_IN TAA-specific_NNP T_NN cells_NNS ._.
        To_TO analyze_VB and_CC compare_VB T_NN cell_NN responses_NNS in_IN melanoma_NN patients_NNS on_IN a_DT single-cell_JJ level_NN ,_, we_PRP
        generated_VBD and_CC examined_VBN a_DT large_JJ number_NN of_IN cytotoxic_JJ T_NN lymphocyte_NN (_( CTL_NNP )_) clones_NNS derived_VBN from_IN
        post-vaccination_JJ or_CC endogenous_JJ anti-tumor_JJ T_NN cell_NN responses_NNS ._. Each_DT clone_NN was_VBD analyzed_VBN for_IN T_NN
        cell_NN receptor_NN (_( TCR_NNP )_) variable_JJ chain_NN beta_NN (_( VB_NNP )_) expression_NN ,_, RE_NNP ,_, and_CC ability_NN to_TO lyse_NN melanoma_NN
        targets_NNS ._. Importantly_NNP ,_, these_DT clones_NNS were_VBD generated_VBN directly_RB ex_FW vivo_NN through_IN tetramer-guided_JJ
        sorting_VBG ,_, which_WDT minimizes_NNS the_DT selection_NN bias_NN that_WDT could_MD be_VB introduced_VBN by_IN prior_JJ in_IN vitro_NN
        expansion_NN ._. Therefore_RB ,_, data_NNS from_IN these_DT clones_NNS could_MD be_VB taken_VBN to_TO estimate_VB the_DT complexity_NN of_IN
        the_DT responses_NNS in_IN vivo_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS and_CC Samples_NNP
          All_DT patients_NNS had_VBD resected_JJ stage_NN III_NNP or_CC IV_NNP melanoma_NN ,_, as_IN determined_VBN by_IN the_DT 1988_CD modified_VBN
          American_NNP Joint_NNP Commission_NNP on_IN Cancer_NNP staging_NN system_NN ._. They_PRP were_VBD required_VBN to_TO have_VB a_DT magnetic_JJ
          resonance_NN imaging_NN or_CC computed_JJ tomographic_JJ scan_VB of_IN the_DT head_NN and_CC computed_JJ tomographic_JJ scans_NNS
          of_IN the_DT chest_NN ,_, abdomen_NN ,_, and_CC pelvis_NNS showing_VBG no_DT indication_NN of_IN disease_NN within_IN 4_CD wk_NN of_IN therapy_NN
          to_TO verify_VB that_IN they_PRP were_VBD clinically_RB free_JJ of_IN melanoma_NN ._. Eligibility_NNP criteria_NNS included_VBD age_NN
          18_CD y_NN or_CC older_JJR ,_, creatinine_NN of_IN less_JJR than_IN 180_CD μmol_NN /_NN l_NN ,_, bilirubin_NN of_IN less_JJR than_IN 110_CD μmol_NN /_NN l_NN ,_,
          platelet_NN count_NN of_IN 100_CD ×_NN 10_CD
          9_CD /_NN l_NN or_CC more_JJR ,_, hemoglobin_NN of_IN 90_CD g_SYM /_NN l_NN or_CC more_JJR ,_, and_CC total_JJ white_JJ blood_NN cell_NN
          count_NN of_IN 3_CD ._. 0_CD ×_NN 10_CD
          9_CD /_NN l_NN or_CC greater_JJR ._. Tests_NNP for_IN human_JJ immunodeficiency_NN virus_NN ,_, hepatitis_NNP C_NNP
          antibody_NN (_( Ab_NNP )_) ,_, and_CC hepatitis_NNP B_NNP surface_NN antigen_NN were_VBD required_VBN to_TO be_VB negative_JJ ,_, and_CC all_DT
          patients_NNS were_VBD HLA-A_NNP 2_CD antigen_NN positive_JJ by_IN a_DT microcytotoxicity_NN assay_NN ._. All_DT patients_NNS were_VBD
          required_VBN to_TO comprehend_NN and_CC sign_VB an_DT informed_VBN consent_NN form_NN approved_VBN by_IN the_DT National_NNP Cancer_NNP
          Institute_NNP (_( NCI_NNP ;_: Bethesda_NNP ,_, Maryland_NNP ,_, United_NNP States_NNPS )_) and_CC the_DT Los_NNP Angeles_NNP County_NNP /_NN University_NNP
          of_IN Southern_NNP California_NNP Institutional_NNP Review_NNP Board_NNP ._. Analysis_NNP of_IN the_DT patient_NN samples_NNS was_VBD
          approved_VBN by_IN Stanford_NNP University_NNP 's_POS Institutional_NNP Review_NNP Board_NNP ._. Peripheral_NNP blood_NN
          mononuclear_NN cell_NN (_( PBMC_NNP )_) samples_NNS were_VBD isolated_VBN from_IN patients_NNS after_IN vaccination_NN with_IN the_DT
          heteroclitic_JJ peptides_NNS MART_NNP 26_CD –_NN 35_CD (_( 27_CD L_NNP )_) (_( ELAGIGILTV_NNP )_) and_CC gp_NN 100_CD 209_CD –_NN 217_CD (_( 210_CD M_NNP )_) (_( IMDQVPSFV_NNP )_)
          at_IN the_DT University_NNP of_IN Southern_NNP California_NNP Norris_NNP Cancer_NNP Center_NNP (_( Los_NNP Angeles_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) ._. Clinical-grade_NNP peptides_NNS used_VBN were_VBD provided_VBN by_IN the_DT Cancer_NNP Therapy_NNP
          Evaluation_NNP Program_NN of_IN the_DT NCI_NNP under_IN an_DT Investigational_NNP New_NNP Drug_NNP application_NN BB_NNP 6123_CD held_VBN
          by_IN the_DT NCI_NNP ._. Immunizations_NNP (_( 1_CD mg_NN of_IN each_DT peptide_NN emulsified_JJ with_IN incomplete_JJ Freund_NNP 's_POS
          adjuvant_NN )_) were_VBD administered_VBN every_DT 2_CD wk_NN for_IN 8_CD wk_NN ,_, then_RB every_DT 4_CD wk_NN for_IN 12_CD wk_NN ,_, and_CC then_RB once_RB
          8_CD wk_NN later_RB ._. PBMC_NNP samples_NNS were_VBD collected_VBN 4_CD wk_NN after_IN the_DT final_JJ immunization_NN and_CC stored_VBD at_IN
          −_NN 130_CD °_NN C_NNP ._. Samples_NNP were_VBD thawed_JJ the_DT day_NN before_IN an_DT experiment_NN for_IN overnight_JJ culture_NN in_IN CTL_NNP
          medium_NN ._. The_DT following_VBG morning_NN ,_, viable_JJ cells_NNS were_VBD isolated_VBN by_IN ficoll_NN density_NN
          centrifugation_NN ,_, washed_VBN ,_, and_CC resuspended_JJ to_TO the_DT appropriate_JJ concentration_NN in_IN a_DT solution_NN of_IN
          90_CD %_NN Iscove_NNP 's_POS Modified_NNP Dulbecco_NNP 's_POS Medium_NNP (_( IMDM_NNP )_) and_CC 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) ._.
        
        
          Flow_NNP Cytometry_NNP Analysis_NNP
          For_IN isolation_NN and_CC detection_NN of_IN peptide-specific_JJ T_NN cells_NNS ,_, patient_NN PBMC_NNP samples_NNS were_VBD
          stained_JJ and_CC analyzed_VBN by_IN fluorescence-activated_JJ cell_NN sorting_VBG (_( FACS_NNP )_) as_RB previously_RB
          described_VBD [_NN 2_CD ]_NN ._. Briefly_NNP ,_, cells_NNS were_VBD stained_JJ with_IN anti-human_JJ CD_NNP 8_CD −_NN fluorescein_NN
          isothiocyanate_NN (_( Caltag_NNP Laboratories_NNPS ,_, Burlingame_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) and_CC
          CD_NNP 19_CD -_: CyChrome_NNP (_( BD_NNP Biosciences_NNP ,_, Palo_NNP Alto_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) Abs_NNP ,_, and_CC
          HLA-A_NNP *_NN 0201_CD /_NN peptide_NN tetramer–phycoerythrin_NN (_( PE_NNP )_) ._. The_DT final_JJ staining_VBG dilution_NN of_IN each_DT Ab_NNP
          was_VBD 1_CD /_NN 200_CD and_CC 1_CD /_NN 80_CD ,_, respectively_RB ._. Tetramer–_NNP PE_NNP was_VBD titrated_JJ for_IN optimal_NN staining_VBG ,_, usually_RB
          between_IN 1_CD and_CC 10_CD μg_NN /_NN ml_NN ._. For_IN TCR_NNP VB_NNP typing_VBG ,_, cells_NNS were_VBD divided_VBN in_IN seven_CD aliquots_NNS and_CC
          stained_JJ with_IN CD_NNP 8_CD PerCP-Cy_NNP 5_CD ._. 5_LS (_( BD_NNP Biosciences_NNP )_) ,_, tetramer–_NN PE_NNP ,_, and_CC a_DT panel_NN of_IN two_CD or_CC three_CD
          different_JJ anti-_NN VB_NNP monoclonal_NN Abs_NNP labeled_VBD with_IN fluorescein_NN isothiocyanate_NN ,_, allophycocyanin_NN
          (_( APC_NNP )_) ,_, or_CC both_DT ._. Cells_NNP were_VBD incubated_JJ at_IN room_NN temperature_NN for_IN 30_CD min_NN ,_, washed_VBN ,_, then_RB
          analyzed_VBD using_VBG a_DT two-laser_JJ ,_, four-color_JJ FACSCalibur_NNP (_( Becton_NNP Dickinson_NNP ,_, Franklin_NNP Lakes_NNP ,_, New_NNP
          Jersey_NNP ,_, United_NNP States_NNPS )_) or_CC sorted_VBN using_VBG a_DT FACSVantage_NNP flow_NN cytometer_NN (_( Becton_NNP Dickinson_NNP )_) ._.
          Lymphocytes_NNP were_VBD identified_VBN by_IN forward_RB and_CC side_NN scatter_NN signals_NNS ,_, then_RB selected_VBN for_IN CD_NNP 8_CD +_NN
          and_CC tetramer_NN positive_JJ ._. Up_IN to_TO one_CD million_CD events_NNS were_VBD acquired_VBN and_CC analyzed_VBN using_VBG FlowJo_NNP
          (_( TreeStar_NNP ,_, San_NNP Carlos_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._.
        
        
          CD_NNP 107_CD Mobilization_NNP Assays_NNP
          
            Target_NNP cells_NNS
            The_DT HLA-A_NNP *_NN 0201_CD -_: positive_JJ melanoma_NN lines_NNS Malme-_NNP 3_CD M_NNP and_CC A_DT 375_CD and_CC the_DT T_NN 2_CD cell_NN line_NN were_VBD
            purchased_VBN from_IN ATCC_NNP (_( Manassas_NNP ,_, Virginia_NNP ,_, United_NNP States_NNPS )_) and_CC maintained_VBN according_VBG to_TO
            instructions_NNS provided_VBN by_IN the_DT ATCC_NNP ._. The_DT HLA-A_NNP *_NN 0201_CD -_: positive_JJ melanoma_NN line_NN mel_NN 526_CD was_VBD
            obtained_VBN from_IN the_DT Surgery_NNP Branch_NNP of_IN the_DT NCI_NNP ._. While_IN Malme-_NNP 3_CD M_NNP and_CC mel_NN 526_CD express_VB both_DT
            MART_NNP and_CC gp_NN 100_CD ,_, A_DT 375_CD does_VBZ not_RB express_VB MART_NNP or_CC gp_NN 100_CD and_CC served_VBD as_IN a_DT negative_JJ control_NN ._.
            Expression_NNP (_( or_CC lack_NN thereof_RB )_) of_IN these_DT antigens_NNS by_IN each_DT cell_NN line_NN was_VBD further_RBR confirmed_VBN
            by_IN immunohistochemical_JJ staining_VBG ._. Cells_NNP were_VBD trypsinized_JJ using_VBG Trypsin_NNP /_NN EDTA_NNP solution_NN
            (_( GIBCO_NNP ,_, San_NNP Diego_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) before_IN use_NN ._. T_NN 2_CD cells_NNS were_VBD HLA-A_NNP 2_CD ._. 1_LS +_NN and_CC
            were_VBD pulsed_JJ prior_RB to_TO assays_NNS with_IN peptides_NNS indicated_VBD in_IN the_DT text_NN ._.
          
          
            Effector_NNP cells_NNS
            Effector_NNP cells_NNS ,_, which_WDT include_VBP clones_NNS ,_, cell_NN line_NN ,_, and_CC PBMC_NNP samples_NNS ,_, were_VBD frozen_VBN and_CC
            analyzed_VBN in_IN batches_NNS ._. The_DT cells_NNS were_VBD thawed_JJ the_DT day_NN before_IN an_DT experiment_NN for_IN overnight_JJ
            culture_NN in_IN CTL_NNP medium_NN ._. The_DT following_VBG morning_NN ,_, viable_JJ cells_NNS were_VBD isolated_VBN by_IN ficoll_NN
            density_NN centrifugation_NN ,_, washed_VBN ,_, and_CC resuspended_JJ to_TO the_DT appropriate_JJ concentration_NN
            (_( usually_RB 10_CD
            7_CD /_NN ml_NN )_) in_IN CTL_NNP medium_NN ._.
          
          
            Experimental_NNP procedure_NN
            All_DT assays_NNS were_VBD done_VBN at_IN least_JJS twice_RB ,_, with_IN duplicates_NNS for_IN each_DT condition_NN ._. The_DT
            effector_NN to_TO target_VB (_( E_NNP :_: T_NN )_) ratio_NN used_VBN was_VBD generally_RB 1_CD :_: 2_CD ,_, with_IN 2_CD ×_NN 10_CD
            5_CD for_IN clones_NNS or_CC 10_CD
            6_CD for_IN the_DT cell_NN line_NN and_CC patient_NN PBMC_NNP samples_NNS ._. To_TO each_DT well_RB ,_, the_DT
            following_VBG was_VBD added_VBN in_IN order_NN :_: 1_CD μl_NN of_IN 2_CD mM_NN monensin_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, Missouri_NNP ,_, United_NNP
            States_NNPS )_) in_IN 100_CD %_NN EtOH_NNP ,_, 100_CD μl_NN of_IN target_NN cells_NNS ,_, 100_CD μl_NN of_IN effector_NN cells_NNS ,_, and_CC 1_CD μl_NN of_IN
            CD_NNP 107_CD -_: APC_NNP Abs_NNP ._. The_DT cells_NNS were_VBD mixed_JJ well_RB using_VBG a_DT multichannel_NN pippetor_NN ._. The_DT plate_NN was_VBD
            centrifuged_JJ at_IN 300_CD
            g_SYM for_IN 1_CD min_NN to_TO pellet_NN cells_NNS ,_, then_RB placed_VBN into_IN an_DT incubator_NN at_IN 37_CD °_NN C_NNP
            for_IN 4_CD h_NN ._. After_IN the_DT incubation_NN ,_, the_DT plates_NNS were_VBD centrifuged_JJ to_TO 500_CD
            g_SYM to_TO pellet_NN cells_NNS ,_, and_CC the_DT supernatant_NN was_VBD removed_VBN ._. Cell–cell_NNP
            conjugates_NNS were_VBD disrupted_VBN by_IN washing_VBG the_DT cells_NNS with_IN PBS_NNP supplemented_JJ with_IN 0_CD ._. 02_CD %_NN azide_NN
            and_CC 0_CD ._. 5_CD mM_NN EDTA_NNP ,_, and_CC mixed_JJ vigorously_RB ,_, then_RB stained_JJ with_IN additional_JJ Abs_NNP ._.
          
        
        
          Generation_NNP of_IN CTL_NNP Clones_NNP
          CD_NNP 8_CD +_NN T_NN cell_NN clones_NNS were_VBD derived_VBN by_IN FACSorting_NNP individual_JJ tetramer-positive_JJ cells_NNS from_IN
          PBMC_NNP samples_NNS prepared_VBN for_IN flow_NN cytometry_NN as_IN described_VBN above_IN ._. CD_NNP 8_CD +_NN tetramer-positive_JJ T_NN
          cells_NNS were_VBD sorted_VBN under_IN sterile_JJ conditions_NNS into_IN 96_CD -_: well_RB plates_NNS ,_, one_CD cell_NN per_IN well_RB ,_, using_VBG
          a_DT FACS_NNP Vantage_NNP (_( Becton_NNP Dickinson_NNP )_) ._. Wells_NNP contained_VBD 100_CD μl_NN of_IN CTL_NNP IMDM_NNP ,_, with_IN 10_CD %_NN FBS_NNP ,_, 2_CD %_NN
          human_JJ AB_NNP sera_NN ,_, and_CC penicillin_NN ,_, streptomycin_NN ,_, and_CC L-_NNP glutamine_NN ,_, supplemented_JJ with_IN 100_CD
          units_NNS /_NN ml_NN IL-_NNP 2_CD ._. Sorted_NNP cells_NNS were_VBD expanded_VBN in_IN vitro_NN using_VBG standard_JJ protocols_NNS ._. Briefly_NNP ,_,
          irradiated_JJ feeder_NN cells_NNS (_( JY_NNP cells_NNS and_CC fresh_JJ PBMCs_NNP )_) were_VBD added_VBN to_TO wells_NNS containing_VBG the_DT
          sorted_VBN T_NN cells_NNS ,_, and_CC the_DT 96_CD -_: well_RB plates_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP with_IN 7_CD %_NN CO_NNP
          2_CD to_TO allow_VB for_IN growth_NN ._. Potential_JJ clones_NNS became_VBD visible_JJ around_IN day_NN 14_CD
          and_CC were_VBD then_RB transferred_VBN to_TO 24_CD -_: well_RB plates_NNS containing_VBG 1_CD ml_NN of_IN CTL_NNP medium_NN with_IN 100_CD
          units_NNS /_NN ml_NN IL-_NNP 2_CD ._. Wells_NNP were_VBD selected_VBN based_VBN on_IN cell_NN confluency_NN for_IN expansion_NN and_CC further_JJ
          analysis_NN ._. Clones_NNP confirmed_VBD to_TO be_VB tetramer-positive_JJ were_VBD expanded_VBN in_IN T-_NNP 25_CD flasks_NNS
          containing_VBG irradiated_JJ JY_NNP cells_NNS and_CC fresh_JJ PBMCs_NNP in_IN 25_CD ml_NN of_IN CTL_NNP medium_NN containing_VBG PHA_NNP ._.
          IL-_NNP 2_CD was_VBD added_VBN to_TO a_DT final_JJ concentration_NN of_IN 50_CD units_NNS /_NN ml_NN on_IN day_NN 1_CD and_CC then_RB every_DT 2_CD d_SYM
          thereafter_RB for_IN 2_CD wk_NN ._.
        
        
          Cytotoxic_NNP Assays_NNP
          
            Target_NNP cells_NNS
            Target_NNP cells_NNS were_VBD as_IN described_VBN above_IN under_IN CD_NNP 107_CD Mobilization_NNP Assays_NNP ,_, and_CC were_VBD
            labeled_VBN overnight_JJ with_IN 
            51_CD Chromium_NNP ,_, washed_VBN ,_, and_CC resuspended_JJ to_TO 10_CD
            5_CD cells_NNS /_NN ml_NN ._. One_CD hundred_CD microliters_NNS of_IN target_NN cells_NNS were_VBD incubated_JJ
            with_IN 100_CD μl_NN CTL_NNP clones_NNS at_IN 10_CD :_: 1_CD E_NNP :_: T_NN ratio_NN for_IN 4_CD h_NN ._. Percent_NN specific_JJ release_NN of_IN 
            51_CD Chromium_NNP from_IN target_NN cells_NNS was_VBD calculated_VBN from_IN 40_CD -_: μl_NN cell-free_JJ
            supernatants_NNS ._.
          
          
            Determination_NNP of_IN RE_NNP
            Chromium-labeled_NNP T_NN 2_CD targets_NNS were_VBD pulsed_JJ with_IN a_DT range_NN of_IN peptide_NN concentrations_NNS ,_,
            generally_RB starting_VBG at_IN 10_CD
            −_NN 7_CD M_NNP and_CC decreasing_VBG by_IN log_NN steps_NNS to_TO 10_CD
            −_NN 13_CD M_NNP ._. T_NN cell_NN clones_NNS were_VBD incubated_JJ with_IN T_NN 2_CD targets_NNS at_IN 10_CD :_: 1_CD E_NNP :_: T_NN
            ratios_NNS for_IN 4_CD h_NN ,_, then_RB chromium_NN release_NN was_VBD measured_VBN and_CC percentage_NN cytotoxicity_NN
            calculated_VBN by_IN standard_JJ methods_NNS ._. Prior_RB to_TO each_DT cytotoxicity_NN assay_NN ,_, clones_NNS underwent_VBD
            ficoll-hypaque_JJ centrifugation_NN to_TO remove_VB dead_JJ feeder_NN cells_NNS and_CC were_VBD determined_VBN to_TO be_VB
            greater_JJR than_IN 80_CD %_NN CD_NNP 8_CD +_NN tetramer-positive_JJ T_NN cells_NNS by_IN FACS_NNP ._. The_DT E_NNP :_: T_NN ratio_NN was_VBD based_VBN upon_IN
            live_VB T_NN and_CC target_NN cells_NNS ._. For_IN each_DT T_NN cell_NN clone_NN ,_, percent_NN cytotoxicity_NN was_VBD plotted_VBD
            against_IN peptide_NN concentration_NN ._. The_DT peptide_NN concentration_NN at_IN which_WDT the_DT curve_NN crossed_VBD 40_CD %_NN
            cytotoxicity_NN was_VBD defined_VBN as_IN the_DT RE_NNP of_IN that_DT clone_NN [_NN 30_CD ]_NN ._.
          
          
            Microcytotoxic_NNP assay_NN
            Cells_NNP were_VBD isolated_VBN directly_RB from_IN PBMCs_NNP from_IN patient_NN 422_CD by_IN FACS_NNP as_IN described_VBN above_IN ._.
            Cells_NNP were_VBD collected_VBN in_IN microfuge_NN tubes_NNS containing_VBG 1_CD ml_NN of_IN ice-cold_JJ 90_CD %_NN IMDM_NNP with_IN 10_CD %_NN
            FBS_NNP ._. Collected_NNP cells_NNS were_VBD washed_VBN and_CC resuspended_JJ to_TO 83_CD ,_, 300_CD cells_NNS /_NN ml_NN in_IN 90_CD %_NN IMDM_NNP with_IN
            10_CD %_NN FBS_NNP ._. Targets_NNP were_VBD prepared_VBN as_IN described_VBN above_IN and_CC resuspended_JJ to_TO 8_CD ,_, 300_CD cells_NNS /_NN ml_NN in_IN
            90_CD %_NN IMDM_NNP with_IN 10_CD %_NN FBS_NNP ._. A_DT total_NN of_IN 2_CD ,_, 500_CD sorted_VBN cells_NNS (_( 30_CD μl_NN )_) and_CC 250_CD target_NN cells_NNS (_( 30_CD
            μl_NN )_) were_VBD transferred_VBN to_TO a_DT microcentrifuge_NN tube_NN (_( VWR_NNP International_NNP ,_, West_NNP Chester_NNP ,_,
            Pennsylvania_NNP ,_, United_NNP States_NNPS )_) ,_, centrifuged_JJ 1_CD min_NN at_IN 200_CD
            g_SYM ,_, and_CC incubated_JJ 4_CD h_NN at_IN 37_CD °_NN C_NNP ._. Percent_NN specific_JJ release_NN of_IN 
            51_CD Chromium_NNP was_VBD calculated_VBN from_IN 40_CD μl_NN of_IN cell-free_JJ supernatant_NN ._.
          
        
        
          TCR_NNP VB_NNP Spectratyping_NNP
          RNA_NNP was_VBD extracted_VBN from_IN clones_NNS and_CC tetramer-positive_JJ cells_NNS using_VBG TRIzol_NNP (_( Invitrogen_NNP ,_,
          Carlsbad_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) and_CC reverse-transcribed_JJ into_IN cDNA_NN using_VBG SuperScript_NNP
          II_NNP Reverse_VBP Transcriptase_NNP (_( Invitrogen_NNP )_) ._. PCR_NNP was_VBD performed_VBN using_VBG 34_CD different_JJ 5_CD ′_NN primers_NNS
          that_WDT specifically_RB amplify_VB all_DT functional_JJ TCR_NNP VB_NNP genes_NNS ._. Most_JJS of_IN the_DT 5_CD ′_NN primers_NNS used_VBN have_VBP
          been_VBN previously_RB described_VBN [_NN 31_CD ]_NN ._. These_DT primers_NNS were_VBD used_VBN in_IN combination_NN with_IN a_DT common_JJ 3_CD ′_NN
          primer_NN based_VBN in_IN the_DT beta_NN chain_NN constant_JJ region_NN ,_, BC_NNP 63_CD (_( 5_CD ′_NN -_: GTGTGGCCTTTTGGGTGT-_NNP 3_CD ′_NN )_) ._. As_IN an_DT
          internal_JJ control_NN ,_, PCR_NNP for_IN a_DT section_NN of_IN the_DT beta_NN chain_NN constant_JJ region_NN was_VBD performed_VBN in_IN
          parallel_JJ with_IN VB-specific_NNP PCRs_NNP using_VBG the_DT following_JJ primers_NNS :_: UpBC_NNP (_( 5_CD ′_NN -_:
          CGCTGTGTTTGAGCCATC-_NNP 3_CD ′_NN )_) and_CC LoBC_NNP (_( 5_CD ′_NN -_: TGCTCAGGCAGTATCTGGA-_NNP 3_CD ′_NN )_) ._. All_DT primer_NN concentrations_NNS
          were_VBD 200_CD nM_NN ._. PCR_NNP was_VBD performed_VBN using_VBG an_DT iCycler_NN iQ_NN thermic_JJ cycler_NN equipped_VBN with_IN a_DT
          real-time_JJ detection_NN system_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) and_CC a_DT
          QuantiTect_NNP SYBR_NNP Green_NNP PCR_NNP kit_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._. PCR_NNP
          reactions_NNS were_VBD performed_VBN as_IN follows_VBZ :_: 94_CD °_NN C_NNP for_IN 9_CD min_NN ,_, followed_VBN by_IN 50_CD cycles_NNS of_IN 94_CD °_NN C_NNP for_IN
          30_CD s_VBZ ,_, 58_CD °_NN C_NNP for_IN 1_CD min_NN ,_, and_CC 72_CD °_NN C_NNP for_IN 1_CD min_NN ,_, followed_VBN by_IN 72_CD °_NN C_NNP for_IN 10_CD min_NN ._. Specific_JJ
          amplification_NN was_VBD determined_VBN relative_JJ to_TO constant_JJ region_NN control_NN PCR_NNP ._. For_IN spectratyping_VBG ,_,
          PCRs_NNP were_VBD performed_VBN as_IN described_VBN above_IN with_IN the_DT following_VBG VB_NNP 14_CD -_: and_CC VB_NNP 17_CD -_: specific_JJ 5_CD ′_NN
          primers_NNS :_: VB_NNP 14_CD m_NN (_( 5_CD ′_NN -_: ACCCAAGATACCTCATCACAG-_NNP 3_CD ′_NN )_) and_CC VB_NNP 17_CD (_( 5_CD ′_NN -_: GACAGGACCCAGGGCAAG-_NNP 3_CD ′_NN )_) ,_,
          followed_VBN by_IN a_DT run-off_JJ PCR_NNP with_IN downstream_JJ VB-specific_NNP primers_NNS :_: VB_NNP 14_CD (_( 5_CD ′_NN -_:
          GGGCTTAAGGCAGATCTACT-_NNP 3_CD ′_NN )_) and_CC VB_NNP 17_CD m_NN (_( 5_CD ′_NN -_: TTTCAGAAAGGAGATATAGCT-_NNP 3_CD ′_NN )_) ,_, and_CC FAM_NNP 6_CD -_: labeled_VBN BC_NNP 63_CD
          3_CD ′_NN primer_NN ._. Run-off_NNP PCR_NNP was_VBD performed_VBN as_IN described_VBN above_IN except_IN that_DT only_RB five_CD cycles_NNS of_IN
          PCR_NNP were_VBD run_VBN with_IN the_DT 55_CD °_NN C_NNP annealing_VBG temperature_NN and_CC QuantiTect_NNP Probe_NNP PCR_NNP kit_NN (_( Qiagen_NNP )_) ._.
          Labeled_NNP PCR_NNP fragments_NNS were_VBD run_VBN on_IN an_DT ABI_NNP Prism_NNP 377_CD DNA_NNP Sequencer_NNP (_( Applied_NNP Biosystems_NNP ,_,
          Foster_NNP City_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) and_CC analyzed_VBD using_VBG GeneScan_NNP software_NN (_( Applied_NNP
          Biosystems_NNP )_) ._.
        
        
          Statistical_NNP Analysis_NNP
          A_DT standard_JJ software_NN package_NN (_( SigmaPlot_NNP 5_CD ._. 0_CD ,_, Systat_NNP Software_NNP ,_, Richmond_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) was_VBD used_VBN to_TO provide_VB descriptive_JJ statistical_JJ plots_NNS ._. Barcharts_NNP were_VBD provided_VBN
          with_IN standard_JJ errors_NNS on_IN them_PRP ._. Linear_NNP plots_NNS were_VBD provided_VBN with_IN standard_JJ errors_NNS computed_JJ at_IN
          each_DT point_NN ._. A_DT linear_JJ regression_NN (_( using_VBG least_JJS squares_NNS )_) of_IN percent_NN specific_JJ lysis_NNS on_IN
          recognition_NN efficiency_NN is_VBZ shown_VBN in_IN Figure_NN 5_CD A_DT and_CC 5_CD B_NNP ._.
        
      
      
        Results_NNS
        
          T_NN Cell_NNP Responses_NNS to_TO TAAs_NNP in_IN Patients_NNPS with_IN Melanoma_NNP
          To_TO address_VB the_DT complexity_NN of_IN T_NN cell_NN responses_NNS against_IN melanoma_NN in_IN vivo_NN ,_, patients_NNS with_IN
          vaccine-induced_JJ or_CC endogenous_JJ TAA-specific_NNP responses_NNS were_VBD selected_VBN ._. In_IN recent_JJ cancer_NN
          vaccine_NN trials_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ,_, many_JJ melanoma_NN patients_NNS who_WP received_VBD heteroclitic_JJ peptide_NN vaccines_NNS
          gp_NN 100_CD 209_CD –_NN 217_CD (_( 210_CD M_NNP )_) (_( IMDQVPSFV_NNP ;_: G_NNP 209_CD –_NN 2_CD M_NNP )_) and_CC MART_NNP 26_CD –_NN 35_CD (_( 27_CD L_NNP )_) (_( ELAGIGILTV_NNP ;_: M_NNP 26_CD )_) had_VBD
          measurable_JJ CD_NNP 8_CD +_NN peptide-specific_JJ T_NN cell_NN responses_NNS in_IN PBMCs_NNP detected_VBN by_IN peptide–_NN MHC_NNP
          tetramer_NN staining_VBG ._. In_IN addition_NN ,_, TAA-specific_NNP T_NN cell_NN responses_NNS could_MD be_VB detected_VBN in_IN some_DT
          patients_NNS without_IN vaccination_NN ,_, suggesting_VBG the_DT existence_NN of_IN an_DT endogenous_JJ anti-tumor_JJ T_NN cell_NN
          response_NN in_IN these_DT patients_NNS ._. For_IN the_DT current_JJ study_NN ,_, we_PRP selected_VBD samples_NNS from_IN six_CD melanoma_NN
          patients_NNS from_IN these_DT trials—four_NN with_IN vaccine-elicited_JJ responses_NNS (_( patients_NNS 422_CD ,_, 476_CD ,_, 517_CD ,_,
          and_CC 520_CD )_) and_CC two_CD with_IN endogenous_JJ T_NN cell_NN responses_NNS (_( patients_NNS 132_CD and_CC 461_CD )_) —_NN for_IN detailed_JJ
          analyses_NNS of_IN TCR_NNP VB_NNP usage_NN ,_, RE_NNP for_IN the_DT target_NN peptide_NN ,_, and_CC tumor_NN cytotoxicity_NN ._. The_DT samples_NNS
          from_IN these_DT six_CD patient_NN had_VBD peptide-specific_JJ T_NN cell_NN populations_NNS detectable_JJ with_IN
          G_NNP 209_CD –_NN 2_CD M-_NNP tetramers_NNS (_( patients_NNS 422_CD ,_, 476_CD ,_, and_CC 132_CD )_) or_CC M_NNP 26_CD -_: tetramers_NNS (_( patients_NNS 517_CD ,_, 520_CD ,_, and_CC
          461_CD )_) ranging_VBG from_IN 0_CD ._. 1_CD %_NN to_TO 2_CD ._. 5_CD %_NN of_IN total_JJ CD_NNP 8_CD +_NN T_NN cells_NNS (_( Figure_NN 1_CD A_DT )_) ._.
        
        
          Vaccine-_NNP Elicited_NNP T_NN Cells_NNP Are_VBP Functional_NNP Directly_NNP Ex_NNP Vivo_NNP but_CC of_IN Variable_NNP Tumor_NNP
          Reactivity_NNP
          Patient_NNP 422_CD had_VBD the_DT largest_JJS detectable_JJ TAA-specific_NNP CD_NNP 8_CD +_NN T_NN cell_NN response_NN (_( 2_CD ._. 5_LS %_NN
          G_NNP 209_CD –_NN 2_CD M-_NNP tetramer-positive_JJ )_) and_CC thus_RB sufficient_JJ numbers_NNS for_IN examination_NN of_IN lytic_JJ function_NN
          immediately_RB following_VBG isolation_NN ._. To_TO test_VB whether_IN peptide-vaccine-induced_JJ T_NN cell_NN responses_NNS
          were_VBD functionally_RB active_JJ directly_RB ex_FW vivo_NN ,_, T_NN cells_NNS isolated_VBN by_IN G_NNP 209_CD –_NN 2_CD M-_NNP tetramer-guided_JJ
          cell_NN sorting_VBG from_IN patient_NN 422_CD were_VBD tested_VBN for_IN lysis_NNS of_IN peptide-pulsed_JJ and_CC melanoma_NN target_NN
          cells_NNS in_IN microcytotoxic_JJ assays_NNS (_( Figure_NN 1_CD B_NNP )_) ._. The_DT directly_RB isolated_VBN tetramer-positive_JJ T_NN
          cells_NNS from_IN this_DT patient_NN specifically_RB lysed_JJ T_NN 2_CD cells_NNS pulsed_JJ with_IN high_JJ concentrations_NNS (_( 1_CD
          μg_NN /_NN ml_NN )_) of_IN G_NNP 209_CD –_NN 2_CD M_NNP and_CC native_JJ (_( G_NNP 209_CD n_NN )_) peptides_NNS ,_, but_CC not_RB with_IN T_NN 2_CD cells_NNS pulsed_JJ with_IN a_DT
          cytomegalovirus-derived_JJ ,_, HLA-A_NNP *_NN 0201_CD -_: restricted_VBN peptide_NN (_( NLVPMVATV_NNP )_) or_CC melanoma_NN targets_NNS ._.
          This_DT suggests_VBZ that_IN while_IN a_DT significant_JJ portion_NN of_IN the_DT vaccine-elicited_JJ T_NN cells_NNS from_IN
          patient_NN 422_CD may_MD be_VB functional_JJ in_IN vivo_NN ,_, they_PRP did_VBD not_RB have_VB significant_JJ tumor_NN lysis_NNS
          activity_NN ._.
          To_TO assess_VB the_DT functional_JJ status_NN of_IN the_DT smaller_JJR TAA-specific_NNP CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS in_IN
          the_DT other_JJ five_CD patients—which_NN were_VBD too_RB small_JJ for_IN direct_JJ cytotoxicity_NN assays_NNS after_IN
          sorting—we_NN utilized_JJ a_DT novel_JJ FACS_NNP assay_NN for_IN degranulation_NN based_VBN on_IN CD_NNP 107_CD mobilization_NN
          [_NN 24_CD ]_NN ._. All_DT six_CD TAA-specific_NNP populations_NNS exhibited_VBN robust_JJ functional_JJ responses_NNS ex_FW vivo_NN ,_, as_IN
          measured_VBN by_IN percentage_NN of_IN G_NNP 2090_CD –_NN 2_CD M-_NNP and_CC M_NNP 26_CD -_: tetramer-positive_JJ cells_NNS that_WDT mobilized_VBD CD_NNP 107_CD
          and_CC /_NN or_CC downregulated_JJ the_DT CD_NNP 3_CD complex_JJ upon_IN incubation_NN with_IN T_NN 2_CD cells_NNS pulsed_JJ with_IN cognate_NN
          peptides_NNS (_( Table_NNP 1_CD ;_: 86_CD %_NN -_: 99_CD ._. 6_CD %_NN )_) ._. In_IN response_NN to_TO melanoma_NN targets_NNS mel_NN 526_CD and_CC Malme-_NNP 3_CD M_NNP ,_, which_WDT
          both_DT express_JJ gp_NN 100_CD and_CC MART-_NNP 1_CD and_CC are_VBP HLA-A_NNP *_NN 0201_CD positive_JJ ,_, the_DT two_CD endogenous_JJ
          TAA-specific_NNP responses_NNS (_( samples_NNS from_IN patients_NNS 132_CD and_CC 461_CD )_) also_RB exhibited_VBN robust_JJ
          functional_JJ responses_NNS directly_RB ex_FW vivo_NN (_( Table_NNP 1_CD ;_: 36_CD ._. 8_CD %_NN –_NN 87_CD %_NN )_) ,_, and_CC these_DT responses_NNS were_VBD
          specific_JJ as_IN they_PRP had_VBD little_JJ response_NN to_TO A_DT 375_CD ,_, a_DT HLA-A_NNP *_NN 0201_CD -_: positive_JJ melanoma_NN cell_NN that_WDT
          does_VBZ not_RB express_VB gp_NN 100_CD or_CC MART-_NNP 1_CD and_CC served_VBD as_IN a_DT negative_JJ control_NN for_IN antigen-specific_JJ
          killing_NN (_( Table_NNP 1_CD ;_: 2_CD ._. 7_CD %_NN and_CC 3_CD %_NN )_) ._. In_IN contrast_NN ,_, the_DT vaccine-elicited_JJ responses_NNS exhibited_VBN
          much_RB lower_JJR reactivity_NN to_TO mel_NN 526_CD and_CC Malme-_NNP 3_CD M_NNP (_( Table_NNP 1_CD ;_: 23_CD ._. 8_CD %_NN –_NN 32_CD ._. 5_LS %_NN )_) ._. These_DT data_NNS
          demonstrate_VBP that_IN all_DT six_CD TAA-specific_NNP CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS were_VBD functional_JJ ex_FW vivo_NN ,_, but_CC
          there_EX were_VBD significant_JJ differences_NNS in_IN reactivity_NN to_TO melanoma_NN targets_NNS between_IN endogenous_JJ
          and_CC vaccine-elicited_JJ responses_NNS ._.
          To_TO substantiate_VB the_DT generality_NN of_IN these_DT findings_NNS ,_, we_PRP analyzed_VBD four_CD additional_JJ patients_NNS
          with_IN vaccine-elicited_JJ responses_NNS ._. One_CD subject_NN responded_VBD to_TO G_NNP 209_CD –_NN 2_CD M_NNP only_RB (_( patient_NN 722_CD )_) ,_, one_CD
          to_TO M_NNP 26_CD only_RB (_( patient_NN 713_CD )_) ,_, and_CC two_CD to_TO both_DT G_NNP 209_CD –_NN 2_CD M_NNP and_CC M_NNP 26_CD (_( patients_NNS 721_CD and_CC 735_CD )_) ._.
          Similar_JJ to_TO the_DT first_JJ four_CD vaccine-elicited_JJ patients_NNS ,_, these_DT four_CD additional_JJ patients_NNS (_( six_CD
          TAA-specific_NNP responses_NNS in_IN total_JJ )_) exhibited_VBN variable_JJ reactivity_NN to_TO melanoma_NN targets_NNS ,_,
          ranging_VBG from_IN 13_CD %_NN to_TO 49_CD ._. 6_CD %_NN (_( Table_NNP 1_LS )_) ._.
        
        
          Vaccine-_NNP Elicited_NNP T_NN Cells_NNP Have_VBP Varied_NNP Capacity_NNP to_TO Lyse_NNP Melanoma_NNP Targets_NNP
          To_TO confirm_VB and_CC further_JJ investigate_VB the_DT differences_NNS in_IN tumor_NN reactivity_NN between_IN
          endogenous_JJ and_CC vaccine-elicited_JJ responses_NNS ,_, we_PRP reasoned_VBD that_DT analysis_NN of_IN a_DT set_NN of_IN clonal_NN
          CTL_NNP lines_NNS that_WDT represented_VBD the_DT tetramer-positive_JJ population_NN would_MD provide_VB an_DT accurate_JJ
          estimate_NN of_IN the_DT complexity_NN of_IN the_DT TAA-specific_NNP T_NN cell_NN response_NN in_IN each_DT patient_NN ._. A_DT large_JJ
          number_NN of_IN clonal_NN CTL_NNP lines_NNS (_( more_JJR than_IN 200_CD )_) were_VBD generated_VBN by_IN FACS_NNP of_IN individual_JJ G_NNP 209_CD –_NN 2_CD M-_NNP
          and_CC M_NNP 26_CD -_: tetramer-positive_JJ cells_NNS directly_RB from_IN PBMC_NNP samples_NNS (_( Table_NNP 2_LS )_) ._. Up_IN to_TO 85_CD %_NN of_IN sorted_VBN
          cells_NNS expanded_VBN in_IN various_JJ sorts_NNS (_( data_NNS not_RB shown_VBN )_) ._. Randomly_NNP selected_VBD expanding_VBG clones_NNS and_CC
          the_DT tetramer-positive_JJ population_NN from_IN which_WDT they_PRP were_VBD derived_VBN were_VBD examined_VBN for_IN TCR_NNP VB_NNP
          expression_NN using_VBG TCR_NNP VB-specific_NNP monoclonal_NN Abs_NNP and_CC VB-specific_NNP primers_NNS in_IN PCR_NNP ._. Diverse_NNP
          TAA-specific_NNP T_NN cell_NN responses_NNS were_VBD found_VBN in_IN the_DT four_CD vaccinated_JJ patients_NNS ,_, with_IN multiple_JJ T_NN
          cells_NNS expressing_VBG different_JJ TCR_NNP VB_NNP ,_, while_IN the_DT two_CD endogenous_JJ responses_NNS were_VBD less_RBR diverse_JJ ._.
          All_DT but_CC one_CD clone_NN derived_VBN from_IN patient_NN 132_CD expressed_VBD VB_NNP 17_CD ,_, while_IN two_CD dominating_VBG T_NN cell_NN
          populations_NNS in_IN patient_NN 476_CD expressed_VBD VB_NNP 14_CD and_CC VB_NNP 17_CD (_( Table_NNP 2_LS )_) ._. The_DT clonality_NN of_IN the_DT
          dominant_JJ populations_NNS in_IN these_DT patients_NNS was_VBD evaluated_VBN by_IN PCR_NNP fragment_NN length_NN analysis_NN
          (_( Table_NNP 3_LS )_) ._. Identical_NNP length_NN fragments_NNS were_VBD demonstrated_VBN in_IN the_DT four_CD selected_VBN clones_NNS from_IN
          476_CD BV_NNP 14_CD +_NN and_CC 476_CD BV_NNP 17_CD +_NN populations_NNS ._. Identical_NNP length_NN fragments_NNS were_VBD also_RB demonstrated_VBN in_IN
          all_DT BV_NNP 17_CD +_NN clones_NNS from_IN patient_NN 132_CD ._. Furthermore_RB ,_, analysis_NN of_IN sorted_VBN tetramer-positive_JJ
          cells_NNS from_IN patient_NN 476_CD demonstrated_VBN single_JJ fragment_NN sizes_NNS for_IN BV_NNP 14_CD and_CC BV_NNP 17_CD ,_, which_WDT were_VBD
          identical_JJ to_TO the_DT fragment_NN sizes_NNS generated_VBN from_IN the_DT selected_VBN clones_NNS ,_, arguing_VBG for_IN clonality_NN
          of_IN these_DT dominant_JJ populations_NNS (_( Table_NNP 3_LS )_) ._.
          Peptide_NNP specificity_NN and_CC CD_NNP 8_CD expression_NN of_IN each_DT clone_NN was_VBD confirmed_VBN by_IN staining_VBG with_IN
          G_NNP 209_CD –_NN 2_CD M-_NNP and_CC M_NNP 26_CD -_: tetramers_NNS and_CC anti-_NN CD_NNP 8_CD monoclonal_NN Ab_NNP (_( data_NNS not_RB shown_VBN )_) ._. To_TO obtain_VB an_DT
          accurate_JJ reflection_NN of_IN the_DT total_JJ T_NN cell_NN population_NN detected_VBD with_IN tetramer_NN in_IN each_DT
          patient_NN ,_, we_PRP decided_VBD to_TO rigorously_RB examine_VB at_IN least_JJS one_CD representative_NN clone_NN for_IN each_DT
          subpopulation_NN expressing_VBG a_DT different_JJ TCR_NNP VB_NNP (_( Table_NNP 4_LS )_) ._. Multiple_NNP clones_NNS were_VBD analyzed_VBN to_TO
          determine_VB dominating_VBG populations_NNS ._. From_IN patients_NNS 132_CD ,_, 517_CD ,_, and_CC 461_CD ,_, for_IN which_WDT fewer_JJR clones_NNS
          were_VBD generated_VBN ,_, all_DT clones_NNS were_VBD included_VBN in_IN the_DT analyses_NNS (_( Table_NNP 4_LS )_) ._.
          To_TO determine_VB the_DT effectiveness_NN of_IN tumor_NN lysis_NNS by_IN the_DT different_JJ TAA-specific_NNP T_NN cell_NN
          clones_NNS that_WDT were_VBD propagated_JJ ,_, clones_NNS were_VBD analyzed_VBN for_IN their_PRP$ ability_NN to_TO lyse_NN melanoma_NN cell_NN
          lines_NNS mel_NN 526_CD and_CC Malme-_NNP 3_CD M_NNP ._. A_DT 375_CD cells_NNS served_VBD as_IN a_DT control_NN for_IN antigen-specific_JJ killing_NN ._.
          In_IN addition_NN ,_, each_DT CTL_NNP clone_NN was_VBD examined_VBN for_IN antigen-specific_JJ lysis_NNS of_IN T_NN 2_CD cells_NNS pulsed_JJ
          with_IN high_JJ levels_NNS (_( 1_CD μg_NN /_NN ml_NN )_) of_IN G_NNP 209_CD –_NN 2_CD M_NNP or_CC M_NNP 26_CD peptides_NNS ._. “ Efficient_NNP lysis_NNS” in_IN these_DT
          experiments_NNS was_VBD defined_VBN as_IN 40_CD %_NN or_CC greater_JJR specific_JJ release_NN of_IN radiolabel_NN from_IN the_DT target_NN
          cells_NNS ;_: 10_CD %_NN or_CC less_RBR specific_JJ release_NN was_VBD categorized_VBN as_IN “ low_JJ or_CC no_DT lysis_NNS ,_,” and_CC 10_CD %_NN to_TO 40_CD %_NN
          was_VBD termed_VBN “ intermediate_JJ lysis_NNS ._.” All_DT but_CC two_CD of_IN the_DT CTL_NNP clones_NNS elicited_JJ from_IN endogenous_JJ
          anti-tumor_JJ responses_NNS (_( from_IN patients_NNS 132_CD and_CC 461_CD )_) exhibited_VBN “ efficient_JJ lysis_NNS” of_IN both_DT the_DT
          mel_NN 526_CD and_CC Malme-_NNP 3_CD M_NNP melanoma_NN cell_NN lines_NNS (_( Figure_NN 2_LS )_) ._. In_IN contrast_NN ,_, only_RB a_DT few_JJ clones_NNS from_IN
          the_DT vaccine-elicited_JJ responses_NNS (_( from_IN patients_NNS 422_CD ,_, 476_CD ,_, 520_CD ,_, and_CC 517_CD )_) efficiently_RB lysed_JJ
          melanoma_NN cells_NNS ._. The_DT majority_NN of_IN clones_NNS examined_VBD from_IN these_DT vaccine-elicited_JJ responses_NNS
          either_CC failed_VBD to_TO lyse_NN melanoma_NN targets_NNS altogether_RB or_CC lysed_JJ them_PRP with_IN intermediate_JJ
          efficiency_NN (_( Figure_NN 2_LS )_) ._. This_DT lack_NN of_IN efficiency_NN in_IN melanoma_NN cell_NN lysis_NNS was_VBD not_RB due_JJ to_TO
          cellular_JJ dysfunction_NN ,_, since_IN each_DT clone_NN efficiently_RB lysed_JJ T_NN 2_CD cells_NNS pulsed_JJ with_IN high_JJ levels_NNS
          of_IN relevant_JJ ,_, but_CC not_RB irrelevant_JJ ,_, peptide_NN (_( Figure_NN 2_LS )_) ._. Overall_RB ,_, the_DT majority_NN of_IN clones_NNS
          derived_VBN from_IN endogenous_JJ anti-tumor_JJ responses_NNS (_( patients_NNS 132_CD and_CC 461_CD )_) lysed_JJ both_DT mel_NN 526_CD and_CC
          Malme-_NNP 3_CD M_NNP melanoma_NN target_NN cells_NNS more_RBR efficiently_RB than_IN clones_NNS from_IN vaccine-elicited_JJ
          responses_NNS (_( patients_NNS 422_CD ,_, 476_CD ,_, 520_CD ,_, and_CC 517_CD )_) (_( Figure_NN 3_LS )_) ._. These_DT findings_NNS suggest_VBP that_IN
          TAA-specific_NNP T_NN cells_NNS elicited_JJ by_IN heteroclitic_JJ peptide_NN vaccination_NN have_VBP different_JJ
          tumor-cytolytic_JJ potentials_NNS from_IN those_DT which_WDT develop_VBP endogenously_RB to_TO cancer_NN ._.
        
        
          RE_NNP for_IN Native_NNP and_CC Heteroclitic_NNP Peptides_NNP of_IN T_NN Cells_NNP from_IN Endogenous_NNP or_CC
          Vaccine-_NNP Elicited_NNP Responses_NNS
          We_PRP hypothesized_VBN that_IN CTL_NNP clones_NNS that_WDT did_VBD not_RB efficiently_RB lyse_NN melanoma_NN targets_NNS may_MD be_VB
          incapable_JJ of_IN recognizing_VBG the_DT relatively_RB low_JJ surface_NN densities_NNS of_IN native_JJ peptide_NN present_JJ
          on_IN tumor_NN cells_NNS ._. CTL_NNP clones_NNS selected_VBN for_IN analysis_NN of_IN tumor_NN lysis_NNS were_VBD also_RB assessed_VBN for_IN RE_NNP
          for_IN the_DT native_JJ and_CC heteroclitic_JJ peptides_NNS via_IN a_DT ten-log_JJ range_NN of_IN dilutions_NNS ._. This_DT is_VBZ
          illustrated_VBN with_IN clones_NNS 132_CD ._. 1_LS and_CC 476_CD ._. 105_CD (_( Figure_NN 4_CD A_DT )_) ._. There_EX were_VBD considerable_JJ
          differences_NNS in_IN killing_NN of_IN peptide-pulsed_JJ T_NN 2_CD cells_NNS by_IN these_DT two_CD clones_NNS ._. The_DT differences_NNS in_IN
          RE_NNP for_IN G_NNP 209_CD n_NN native_JJ peptide_NN displayed_VBN by_IN the_DT two_CD clones_NNS highlighted_VBN in_IN Figure_NN 3_CD A_DT
          correlated_JJ with_IN their_PRP$ ability_NN to_TO lyse_NN melanoma_NN cells_NNS :_: the_DT high-_NN RE_NNP clone_NN 132_CD ._. 1_LS efficiently_RB
          lysed_JJ melanoma_NN targets_NNS ,_, whereas_IN the_DT low-_JJ RE_NNP clone_NN 476_CD ._. 105_CD did_VBD not_RB (_( Figure_NN 4_CD B_NNP )_) ._. In_IN contrast_NN
          to_TO the_DT differences_NNS in_IN RE_NNP for_IN G_NNP 209_CD n_NN peptide_NN ,_, similar_JJ assays_NNS revealed_VBD little_JJ difference_NN in_IN
          RE_NNP of_IN the_DT two_CD clones_NNS for_IN G_NNP 209_CD –_NN 2_CD M_NNP heteroclitic_JJ peptide_NN (_( Figure_NN 4_CD C_NNP )_) ,_, suggesting_VBG that_IN these_DT
          clones_NNS recognize_VBP the_DT native_JJ and_CC heteroclitic_JJ peptides_NNS differently_RB ,_, and_CC that_IN RE_NNP for_IN the_DT
          native_NN ,_, but_CC not_RB heteroclitic_JJ ,_, peptide_NN correlates_NNS with_IN tumor-lytic_JJ potential_NN ._.
          Similar_JJ RE_NNP assays_NNS were_VBD performed_VBN for_IN the_DT remaining_VBG clones_NNS from_IN each_DT patient_NN selected_VBN
          for_IN analysis_NN ._. In_IN order_NN to_TO compare_VB REs_NNP of_IN various_JJ CTL_NNP lines_NNS ,_, each_DT clone_NN was_VBD assigned_VBN an_DT RE_NNP
          score_NN expressed_VBD as_IN the_DT negative_JJ log_NN
          10_CD value_NN of_IN the_DT peptide_NN concentration_NN required_VBN for_IN 40_CD %_NN specific_JJ lysis_NNS
          at_IN an_DT E_NNP :_: T_NN ratio_NN of_IN 10_CD :_: 1_CD ._. For_IN clones_NNS 132_CD ._. 1_LS and_CC 476_CD ._. 105_CD ,_, these_DT scores_NNS were_VBD 11_CD ._. 1_LS and_CC 8_CD ._. 3_CD for_IN
          assays_NNS with_IN G_NNP 209_CD n_NN peptide_NN (_( Figure_NN 4_CD A_DT )_) ,_, and_CC 11_CD ._. 2_LS and_CC 11_CD ._. 2_LS for_IN assays_NNS with_IN G_NNP 209_CD –_NN 2_CD M_NNP
          heteroclitic_JJ peptide_NN (_( Figure_NN 4_CD C_NNP )_) ,_, respectively_RB ._. We_PRP compiled_VBN the_DT data_NNS on_IN clones_NNS from_IN all_DT
          patients_NNS ,_, which_WDT showed_VBD a_DT correlation_NN between_IN tumor-lytic_JJ potential_JJ and_CC RE_NNP for_IN native_JJ
          peptide_NN (_( Figure_NN 5_CD A_DT and_CC 5_CD B_NNP )_) ._. Overall_RB ,_, clones_NNS generated_VBN from_IN endogenous_JJ anti-tumor_JJ
          responses_NNS had_VBD higher_JJR RE_NNP for_IN the_DT native_JJ peptide_NN than_IN clones_NNS generated_VBN from_IN post-vaccine_JJ
          responses_NNS (_( Figure_NN 5_CD C_NNP and_CC 5_CD D_NNP )_) ._. We_PRP estimated_VBD the_DT composite_JJ RE_NNP of_IN the_DT overall_JJ TAA-specific_NNP
          response_NN (_( composed_VBN of_IN a_DT heterogeneous_JJ population_NN of_IN T_NN cells_NNS )_) in_IN vivo_NN by_IN summing_VBG the_DT RE_NNP of_IN
          each_DT clone_NN multiplied_VBN by_IN its_PRP$ representation_NN in_IN the_DT original_JJ mixture_NN (_( the_DT representation_NN
          was_VBD estimated_VBN based_VBN on_IN the_DT proportion_NN of_IN TAA-specific_NNP cells_NNS expressing_VBG the_DT same_JJ VB_NNP as_IN the_DT
          clone_NN )_) ._. These_DT composite_JJ RE_NNP values_NNS are_VBP represented_VBN in_IN Figure_NN 5_CD as_IN horizontal_NN bars_NNS for_IN each_DT
          response_NN ._. Clearly_RB ,_, the_DT endogenous_JJ responses_NNS (_( patients_NNS 461_CD and_CC 132_CD )_) had_VBD a_DT higher_JJR overall_JJ ,_,
          and_CC more_RBR homogeneous_JJ ,_, RE_NNP for_IN the_DT native_JJ peptide_NN than_IN the_DT vaccine-elicited_JJ responses_NNS
          (_( patients_NNS 422_CD ,_, 476_CD ,_, 517_CD ,_, and_CC 520_CD )_) (_( Figure_NN 5_CD C_NNP and_CC 5_CD D_NNP )_) ._. Importantly_NNP ,_, the_DT vaccine-elicited_JJ
          clones_NNS also_RB exhibited_VBN wide_JJ variations_NNS in_IN RE_NNP even_RB for_IN the_DT heteroclitic_JJ peptide_NN ,_, compared_VBN
          to_TO the_DT endogenous_JJ responses_NNS (_( Figure_NN 5_CD E_NNP and_CC 5_CD F_NN )_) ._. This_DT suggests_VBZ that_IN the_DT variation_NN in_IN RE_NNP
          for_IN native_JJ peptides_NNS ,_, and_CC hence_RB ability_NN to_TO lyse_NN tumor_NN cells_NNS ,_, for_IN vaccine-elicited_JJ
          responses_NNS is_VBZ not_RB merely_RB a_DT reflection_NN of_IN differential_NN recognition_NN of_IN native_JJ and_CC
          heteroclitic_JJ peptides_NNS by_IN many_JJ clones_NNS ._. Rather_RB ,_, variations_NNS in_IN RE_NNP may_MD be_VB a_DT function_NN of_IN the_DT
          manner_NN in_IN which_WDT these_DT cells_NNS were_VBD elicited_JJ in_IN vivo_NN via_IN vaccination_NN ._.
        
      
      
        Discussion_NNP
        To_TO achieve_VB maximal_NN clinical_JJ responses_NNS ,_, the_DT majority_NN of_IN T_NN cells_NNS elicited_JJ by_IN vaccination_NN
        in_IN cancer_NN patients_NNS should_MD be_VB capable_JJ of_IN responding_VBG to_TO tumor_NN targets_NNS ._. We_PRP have_VBP undertaken_VBN the_DT
        most_RBS detailed_JJ analysis_NN to_TO date_NN ,_, on_IN a_DT single-cell_JJ level_NN ,_, of_IN T_NN cell_NN responses_NNS elicited_JJ by_IN
        cancer_NN vaccination_NN and_CC have_VBP compared_VBN these_DT with_IN endogenous_JJ anti-tumor_JJ responses_NNS ._. To_TO
        evaluate_VB the_DT full_JJ spectrum_NN of_IN T_NN cells_NNS elicited_JJ in_IN each_DT patient_NN by_IN vaccination_NN ,_, we_PRP utilized_JJ
        tetramers_NNS made_VBN with_IN the_DT vaccine_NN peptides_NNS (_( heteroclitic_JJ M_NNP 26_CD and_CC G_NNP 209_CD –_NN 2_CD M_NNP )_) to_TO isolate_VB such_JJ
        cells_NNS ._. CTL_NNP clones_NNS were_VBD selected_VBN directly_RB from_IN patient_NN PBMC_NNP samples_NNS without_IN enrichment_NN in_IN
        culture_NN to_TO closely_RB reflect_VB the_DT composition_NN of_IN the_DT antigen-specific_JJ T_NN cell_NN response_NN in_IN vivo_NN
        at_IN the_DT time_NN of_IN isolation_NN ._.
        Our_PRP$ data_NNS revealed_VBD that_DT T_NN cell_NN populations_NNS induced_VBN by_IN vaccination_NN were_VBD significantly_RB
        different_JJ from_IN endogenous_JJ responses_NNS :_: while_IN some_DT CTLs_NNP elicited_JJ by_IN vaccination_NN could_MD kill_VB
        melanoma_NN targets_NNS ,_, most_JJS were_VBD inefficient_JJ in_IN tumor_NN cell_NN lysis_NNS ._. In_IN contrast_NN ,_, nearly_RB all_DT clones_NNS
        from_IN endogenous_JJ responses_NNS were_VBD efficient_JJ at_IN melanoma_NN cell_NN lysis_NNS ._. This_DT difference_NN was_VBD
        related_VBN to_TO RE_NNP for_IN the_DT native_JJ peptide_NN ._. Clones_NNP that_WDT did_VBD not_RB lyse_NN tumor_NN cells_NNS required_VBN up_IN to_TO
        10_CD
        3_CD -_: fold_VB higher_JJR concentration_NN of_IN peptide_NN for_IN similar_JJ levels_NNS of_IN lysis_NNS of_IN
        targets_NNS compared_VBN to_TO T_NN cell_NN clones_NNS that_WDT were_VBD tumor-lytic_JJ ._. Side-by-side_NNP comparison_NN of_IN
        endogenous_JJ responses_NNS and_CC vaccine-induced_JJ responses_NNS suggests_VBZ that_IN low_JJ RE_NNP TAA-specific_NNP T_NN cell_NN
        responses_NNS may_MD be_VB preferentially_RB driven_VBN by_IN heteroclitic_JJ peptide_NN vaccination_NN ._. Thus_RB ,_, high_JJ
        doses_NNS of_IN peptide_NN and_CC /_NN or_CC the_DT higher_JJR levels_NNS of_IN expression_NN of_IN heteroclitic_JJ peptide_NN on_IN APCs_NNP may_MD
        induce_VB and_CC actively_RB propagate_NN predominantly_RB T_NN cells_NNS with_IN RE_NNP too_RB low_JJ for_IN recognition_NN of_IN
        physiological_JJ levels_NNS of_IN the_DT native_JJ peptide_NN present_JJ on_IN tumor_NN targets_NNS ._. These_DT data_NNS suggest_VBP an_DT
        inverse_NN relationship_NN between_IN antigen_NN density_NN and_CC the_DT RE_NNP of_IN T_NN cells_NNS elicited_JJ ._. This_DT would_MD be_VB
        an_DT important_JJ consideration_NN in_IN design_NN of_IN future_JJ vaccine_NN strategies_NNS ._.
        Differential_NNP recognition_NN of_IN native_JJ and_CC heteroclitic_JJ peptides_NNS by_IN many_JJ T_NN cells_NNS may_MD also_RB
        account_VB for_IN the_DT induction_NN of_IN non-tumor-lytic_JJ clones_NNS by_IN heteroclitic_JJ peptide_NN vaccines_NNS ,_, which_WDT
        has_VBZ been_VBN suggested_VBN previously_RB [_NN 23_CD ,_, 32_CD ]_NN ._. However_RB ,_, our_PRP$ data_NNS suggest_VBP that_DT epitope_NN density_NN may_MD
        be_VB the_DT dominant_JJ driving_NN factor_NN for_IN RE_NNP in_IN vivo_NN ._. In_IN all_DT of_IN the_DT vaccine-elicited_JJ T_NN cell_NN
        responses_NNS ,_, many_JJ of_IN the_DT T_NN cells_NNS generated_VBN were_VBD either_CC of_IN low_JJ or_CC intermediate_JJ RE_NNP not_RB only_RB for_IN
        the_DT native_JJ peptide_NN ,_, but_CC also_RB for_IN the_DT heteroclitic_JJ peptide_NN ,_, and_CC exhibited_VBN no_DT or_CC intermediate_JJ
        lysis_NNS of_IN tumor_NN targets_NNS ._. In_IN contrast_NN ,_, nearly_RB all_DT of_IN the_DT clones_NNS generated_VBN from_IN the_DT endogenous_JJ
        responses_NNS were_VBD of_IN high_JJ RE_NNP ._. This_DT suggests_VBZ that_IN the_DT high_JJ dosage_NN of_IN peptides_NNS administered_VBN in_IN
        vaccinations_NNS and_CC the_DT increased_VBN binding_JJ capacity_NN of_IN heteroclitic_JJ peptides_NNS to_TO MHC_NNP
        molecules—the_NN very_RB quality_NN that_WDT provides_VBZ them_PRP with_IN increased_VBN immunogenicity—drive_JJ the_DT
        induction_NN of_IN many_JJ T_NN cells_NNS with_IN low_JJ RE_NNP for_IN both_DT heteroclitic_JJ and_CC native_JJ peptides_NNS ._.
        Another_DT implication_NN of_IN this_DT study_NN is_VBZ that_IN the_DT number_NN of_IN cells_NNS measured_VBN by_IN current_JJ
        methods_NNS ,_, including_VBG ELISPOT_NNP or_CC staining_VBG with_IN MHC_NNP tetramers_NNS ,_, may_MD not_RB correlate_VBP directly_RB with_IN
        the_DT RE_NNP or_CC tumor_NN reactivity_NN of_IN T_NN cell_NN responses_NNS to_TO vaccination_NN ._. For_IN example_NN ,_, of_IN the_DT nine_CD
        clones_NNS analyzed_VBD from_IN patient_NN 517_CD ,_, none_NN were_VBD efficient_JJ in_IN tumor_NN cell_NN lysis_NNS ,_, yet_RB these_DT cells_NNS
        were_VBD detectable_JJ by_IN MHC_NNP tetramer_NN staining_VBG ._. T_NN cells_NNS with_IN low_JJ RE_NNP for_IN native_JJ TAA_NNP do_VBP not_RB
        efficiently_RB lyse_NN tumor_NN ,_, and_CC therefore_RB are_VBP unlikely_JJ to_TO have_VB an_DT impact_NN on_IN clinical_JJ outcome_NN ._.
        Furthermore_RB ,_, it_PRP may_MD be_VB possible_JJ that_IN low-_JJ RE_NNP TAA-specific_NNP T_NN cells_NNS may_MD interfere_VB with_IN
        elicitation_NN of_IN high-_NN RE_NNP T_NN cells_NNS ,_, either_CC by_IN direct_JJ competition_NN for_IN antigen_NN on_IN APC_NNP surface_NN
        [_NN 33_CD ,_, 34_CD ]_NN or_CC down-modulation_JJ of_IN peptide–_NN MHC_NNP complexes_NNS ._.
        Our_PRP$ data_NNS support_VBP the_DT notion_NN that_IN not_RB only_RB quantity_NN ,_, but_CC quality_NN ,_, of_IN the_DT T_NN cell_NN response_NN
        elicited_JJ by_IN vaccination_NN may_MD be_VB important_JJ for_IN clinical_JJ efficacy_NN ._. There_EX are_VBP a_DT number_NN of_IN
        strategies_NNS to_TO increase_VB the_DT magnitude_NN of_IN T_NN cell_NN responses_NNS to_TO peptide_NN vaccines_NNS ._. These_DT include_VBP
        using_VBG various_JJ adjuvants_NNS ,_, such_JJ as_IN incomplete_JJ Freund_NNP 's_POS adjuvant_NN and_CC immunomodulatory_NN agents_NNS ,_,
        such_JJ as_IN IL-_NNP 12_CD [_NN 4_CD ]_NN ,_, GM-CSF_NNP [_NN 5_CD ]_NN ,_, anti-_NN CTLA-_NNP 4_CD Abs_NNP [_NN 35_CD ]_NN ,_, or_CC heat_NN shock_NN proteins_NNS [_NN 36_CD ]_NN ._. Thus_RB far_RB ,_,
        none_NN of_IN these_DT approaches_NNS have_VBP produced_VBN improved_VBN clinical_JJ outcomes_NNS ._. Our_PRP$ data_NNS suggest_VBP that_IN in_IN
        addition_NN to_TO driving_VBG higher_JJR numbers_NNS of_IN vaccine-elicited_JJ T_NN cells_NNS ,_, strategies_NNS to_TO modulate_VBP the_DT
        relative_JJ RE_NNP of_IN T_NN cell_NN responses_NNS are_VBP also_RB needed_VBN ._. While_IN the_DT selective_JJ activation_NN of_IN high-_NN
        versus_CC low-_JJ RE_NNP T_NN cells_NNS is_VBZ relatively_RB easy_JJ to_TO manipulate_VB in_IN vitro_NN via_IN stimulation_NN with_IN
        limiting_VBG amounts_NNS of_IN peptides_NNS ,_, this_DT may_MD be_VB more_RBR difficult_JJ to_TO control_VB in_IN vivo_NN ._. It_PRP is_VBZ
        important_JJ to_TO bear_VB in_IN mind_NN that_IN signals_NNS needed_VBN to_TO drive_VB a_DT de_IN novo_NN naïve_NN T_NN cell_NN response_NN may_MD
        be_VB different_JJ from_IN those_DT required_JJ to_TO drive_VB further_JJ expansion_NN of_IN an_DT activated_VBN T_NN cell_NN
        population_NN [_NN 37_CD ]_NN ._. Thus_RB ,_, a_DT complete_JJ vaccination_NN strategy_NN may_MD involve_VB an_DT initial_JJ induction_NN
        phase_NN ,_, followed_VBN by_IN progressive_JJ shaping_VBG of_IN the_DT response_NN to_TO higher_JJR RE_NNP ._. Although_IN heteroclitic_JJ
        peptide_NN vaccination_NN may_MD drive_VB T_NN cells_NNS of_IN mixed_JJ high_JJ and_CC low_JJ RE_NNP ,_, such_JJ a_DT strong_JJ stimulus_NN may_MD
        be_VB needed_VBN to_TO induce_VB an_DT initial_JJ de_IN novo_NN T_NN cell_NN response_NN ._. Studies_NNS in_IN mice_NNS suggest_VBP that_IN once_RB
        activated_VBN ,_, effector_NN CD_NNP 8_CD +_NN T_NN cells_NNS may_MD have_VB an_DT increase_NN in_IN RE_NNP of_IN up_IN to_TO 70_CD -_: fold_VB compared_VBN to_TO
        naïve_NN cells_NNS [_NN 38_CD ,_, 39_CD ,_, 40_CD ]_NN ._. Thus_RB ,_, naïve_NN TAA-specific_NNP T_NN cells_NNS ,_, with_IN inadequate_JJ RE_NNP to_TO become_VB
        activated_VBN by_IN low_JJ densities_NNS of_IN native_JJ peptides_NNS present_JJ on_IN tumor_NN cells_NNS ,_, may_MD become_VB efficient_JJ
        in_IN tumor_NN lysis_NNS upon_IN vaccination_NN with_IN heteroclitic_JJ peptide_NN ._. This_DT notion_NN has_VBZ support_NN from_IN
        studies_NNS in_IN tolerized_JJ mice_NNS :_: vaccination_NN with_IN a_DT heteroclitic_JJ peptide_NN analog_NN recruited_VBD T_NN
        cells_NNS ,_, which_WDT were_VBD responsive_JJ to_TO secondary_JJ stimulation_NN with_IN native_JJ peptide_NN [_NN 41_CD ,_, 42_CD ]_NN ._.
        Therefore_RB ,_, optimized_JJ use_NN of_IN heteroclitic_JJ peptide_NN to_TO induce_VB an_DT initial_JJ peptide-specific_JJ T_NN
        cell_NN response_NN ,_, followed_VBN by_IN selective_JJ expansion_NN of_IN the_DT highest_JJS RE_NNP tumor-lytic_JJ T_NN cells_NNS may_MD be_VB
        needed_VBN for_IN an_DT effective_JJ strategy_NN with_IN clear_JJ clinical_JJ application_NN ._.
        In_IN summary_NN ,_, we_PRP have_VBP demonstrated_VBN that_DT vaccination_NN with_IN heteroclitic_JJ peptide_NN at_IN high_JJ
        concentrations_NNS may_MD drive_VB T_NN cell_NN responses_NNS of_IN variable_JJ tumor-cytolytic_JJ potential_NN in_IN cancer_NN
        patients—and_NN that_IN the_DT ability_NN to_TO lyse_NN tumor_NN cells_NNS correlates_NNS with_IN the_DT T_NN cell_NN 's_POS RE_NNP for_IN
        native_JJ peptides_NNS ._. This_DT represents_VBZ an_DT important—but_NN not_RB sole—factor_NN in_IN explaining_VBG the_DT lack_NN of_IN
        correlation_NN between_IN immunological_JJ and_CC clinical_JJ responses_NNS after_IN vaccination_NN for_IN cancer_NN ._.
        Importantly_NNP ,_, the_DT situation_NN is_VBZ different_JJ in_IN endogenous_JJ responses_NNS ,_, in_IN which_WDT cells_NNS are_VBP
        predominantly_RB of_IN high_JJ RE_NNP ._. This_DT suggests_VBZ that_IN the_DT manner_NN in_IN which_WDT T_NN cells_NNS are_VBP elicited_JJ in_IN
        vivo_NN are_VBP different_JJ in_IN these_DT two_CD settings_NNS and_CC may_MD underlie_VB their_PRP$ differences_NNS in_IN biology_NN ._.
      
    
  
